Navigation Links
Long-term 12-month safety data on ADHD patch DAYTRANA
Date:10/26/2007

BOSTON OCTOBER 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom, reported investigator Frank A. Lpez, M.D., neurodevelopmental pediatrician at the Childrens Developmental Center, Winter Park, Fla. Importantly, this year-long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies.

Shires DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping.

Lpez added, DAYTRANAs novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their childrens changing schedules.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

The study was supported by funding from Shire.


'/>"/>

Contact: Jennifer Anello
212-601-8132
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Small lumps in breast if not treated may cause long-term harm
4. Lung Therapy Found To Have Long-Term Side Effects
5. Long-Term Benefits Of Statins Questioned
6. Long-term use of calcium supplements to prevent colon cancer
7. Survivors of childhood cancer may have long-term health problems
8. Long-term Care Should Be A Planned Affair
9. Pfizer vouches safety of long-term inhaled insulin.
10. Clue to Link Between Obesity and Long-Term Memory Discovered
11. Drug Regulators Need To Think In Long-Term, Say Charities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Chicago, IL (PRWEB) , ... December 07, 2016 , ... ... giving back this holiday season by donating a portion of proceeds to two local ... North Chicago Animal Control & Friends is a team of authorized and ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows ... that follows. , “Fred Rides a Train” is the creation of published author, ... since her teen years in Michigan. The "Fred, the Dog" series is her first ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016 According to a new market research report ... Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), ... expected to reach USD 1,519.2 Million by 2021 from USD 856.3 Million ... Continue Reading ... ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
(Date:12/7/2016)... December 7, 2016 According to ... titled , Global Market Study on Multiplex Detection Immunoassay: North ... , the global multiplex detection immunoassay market is expected to witness ... ... ,      (Logo: ...
Breaking Medicine Technology: